Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Small Molecule Tyrosine Kinase Inhibitors of ErbB2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Authors
Keywords
-
Journal
MOLECULES
Volume 19, Issue 9, Pages 15196-15212
Publisher
MDPI AG
Online
2014-09-23
DOI
10.3390/molecules190915196
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- First results from the phase III ALTTO trial (BIG 2-06; NCCTG [Alliance] N063D) comparing one year of anti-HER2 therapy with lapatinib alone (L), trastuzumab alone (T), their sequence (T→L), or their combination (T+L) in the adjuvant treatment of HER2-positive early breast cancer (EBC).
- (2017) Martine J. Piccart-Gebhart et al. JOURNAL OF CLINICAL ONCOLOGY
- Synergistic apoptosis in head and neck squamous cell carcinoma cells by co-inhibition of insulin-like growth factor-1 receptor signaling and compensatory signaling pathways
- (2015) Mark J. Axelrod et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- A phase IIa dose-finding and safety study of first-line pertuzumab in combination with trastuzumab, capecitabine and cisplatin in patients with HER2-positive advanced gastric cancer
- (2014) Y-K Kang et al. BRITISH JOURNAL OF CANCER
- A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib
- (2014) Karen L. Reckamp et al. CANCER
- Inducible tyrosine kinase inhibitors: a review of the patent literature (2010 – 2013)
- (2014) Peter Norman EXPERT OPINION ON THERAPEUTIC PATENTS
- Small-Molecule Inhibitors of the Receptor Tyrosine Kinases: Promising Tools for Targeted Cancer Therapies
- (2014) Mohammad Hojjat-Farsangi INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: Phase I study in Japanese patients with advanced solid malignancies and advanced breast cancer
- (2014) Takayasu Kurata et al. INVESTIGATIONAL NEW DRUGS
- AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models
- (2014) Zhaomei Mu et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- A phase I study of AST1306, a novel irreversible EGFR and HER2 kinase inhibitor, in patients with advanced solid tumors
- (2014) Jian Zhang et al. Journal of Hematology & Oncology
- Abstract B268: A Phase I Study of CUDC-101, a multitarget inhibitor of HDACs, EGFR, and HER2, in combination with chemoradiation in patients with intermediate/high risk locally advanced squamous cell carcinoma of the head and neck.
- (2014) A. Jimeno et al. MOLECULAR CANCER THERAPEUTICS
- The European Medicines Agency Review of Pertuzumab for the Treatment of Adult Patients With HER2-Positive Metastatic or Locally Recurrent Unresectable Breast Cancer: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use
- (2014) Hector Boix-Perales et al. ONCOLOGIST
- ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors
- (2014) Robert Roskoski PHARMACOLOGICAL RESEARCH
- Design and synthesis of novel pyrimido[4,5- b ]azepine derivatives as HER2/EGFR dual inhibitors
- (2013) Youichi Kawakita et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer
- (2013) Jayalakshmi Sridhar et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Progress in Breast Cancer: Overview
- (2013) C. L. Arteaga CLINICAL CANCER RESEARCH
- Metastasis Dormancy in Estrogen Receptor-Positive Breast Cancer
- (2013) X. H.- F. Zhang et al. CLINICAL CANCER RESEARCH
- Recent Advances in Drug Design of Epidermal Growth Factor Receptor Inhibitors
- (2013) P. Warnault et al. CURRENT MEDICINAL CHEMISTRY
- Targeting receptor tyrosine kinases in HER2-negative breast cancer
- (2013) Gayathri Anandappa et al. CURRENT OPINION IN ONCOLOGY
- Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors
- (2013) S. Tjulandin et al. INVESTIGATIONAL NEW DRUGS
- LUX-Lung 4: A Phase II Trial of Afatinib in Patients With Advanced Non–Small-Cell Lung Cancer Who Progressed During Prior Treatment With Erlotinib, Gefitinib, or Both
- (2013) Nobuyuki Katakami et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of new HER2/EGFR dual kinase inhibitors based on the anilinoquinazoline scaffold as potential anti-cancer agents
- (2013) Maiada M. Sadek et al. JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY
- Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress
- (2013) J. Jean Cui JOURNAL OF MEDICINAL CHEMISTRY
- Optimization of Substituted 6-Salicyl-4-Anilinoquinazoline Derivatives as Dual EGFR/HER2 Tyrosine Kinase Inhibitors
- (2013) Dong-Dong Li et al. PLoS One
- Discovery of AZD8931, an Equipotent, Reversible Inhibitor of Signaling by EGFR, HER2, and HER3 Receptors
- (2013) Bernard Barlaam et al. ACS Medicinal Chemistry Letters
- Design and synthesis of pyrrolo[3,2-d]pyrimidine HER2/EGFR dual inhibitors: Improvement of the physicochemical and pharmacokinetic profiles for potent in vivo anti-tumor efficacy
- (2012) Youichi Kawakita et al. BIOORGANIC & MEDICINAL CHEMISTRY
- Verification of brain penetration of the unbound fraction of a novel HER2/EGFR dual kinase inhibitor (TAK-285) by microdialysis in rats
- (2012) Franciska Erdő et al. BRAIN RESEARCH BULLETIN
- Efficacy of HER2-targeted therapy in metastatic breast cancer. Monoclonal antibodies and tyrosine kinase inhibitors
- (2012) Dorte L. Nielsen et al. BREAST
- Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients
- (2012) T Doi et al. BRITISH JOURNAL OF CANCER
- Targeting HER Receptors in Cancer
- (2012) Alberto Ocana et al. CURRENT PHARMACEUTICAL DESIGN
- Emodin inhibits invasion and migration of prostate and lung cancer cells by downregulating the expression of chemokine receptor CXCR4
- (2012) Sooho Ok et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- Irreversible Protein Kinase Inhibitors: Balancing the Benefits and Risks
- (2012) Tjeerd Barf et al. JOURNAL OF MEDICINAL CHEMISTRY
- Design and Synthesis of Pyrrolo[3,2-d]pyrimidine Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors: Exploration of Novel Back-Pocket Binders
- (2012) Youichi Kawakita et al. JOURNAL OF MEDICINAL CHEMISTRY
- Dacomitinib (PF-00299804), an Irreversible Pan-HER Inhibitor, Inhibits Proliferation of HER2-Amplified Breast Cancer Cell Lines Resistant to Trastuzumab and Lapatinib
- (2012) O. Kalous et al. MOLECULAR CANCER THERAPEUTICS
- Beyond trastuzumab: New treatment options for HER2-positive breast cancer
- (2011) Kamal S. Saini et al. BREAST
- p95HER2 and Breast Cancer
- (2011) J. Arribas et al. CANCER RESEARCH
- Phase I Dose-Escalation Study of the Pan-HER Inhibitor, PF299804, in Patients with Advanced Malignant Solid Tumors
- (2011) P. A. Janne et al. CLINICAL CANCER RESEARCH
- Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein
- (2011) Kathleen Aertgeerts et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Design and Synthesis of Novel Human Epidermal Growth Factor Receptor 2 (HER2)/Epidermal Growth Factor Receptor (EGFR) Dual Inhibitors Bearing a Pyrrolo[3,2-d]pyrimidine Scaffold
- (2011) Tomoyasu Ishikawa et al. JOURNAL OF MEDICINAL CHEMISTRY
- Treatment of HER2-positive breast cancer: current status and future perspectives
- (2011) Carlos L. Arteaga et al. Nature Reviews Clinical Oncology
- AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo
- (2011) Hua Xie et al. PLoS One
- Discovery of selective irreversible inhibitors for EGFR-T790M
- (2010) Wenjun Zhou et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- Novel pyrrolo[2,1-f][1,2,4]triazin-4-amines: Dual inhibitors of EGFR and HER2 protein tyrosine kinases
- (2010) Brian E. Fink et al. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
- EGFR/HER2 inhibitor AEE788 increases ER-mediated transcription in HER2/ER-positive breast cancer cells but functions synergistically with endocrine therapy
- (2010) A H Evans et al. BRITISH JOURNAL OF CANCER
- CUDC-101, a Multitargeted Inhibitor of Histone Deacetylase, Epidermal Growth Factor Receptor, and Human Epidermal Growth Factor Receptor 2, Exerts Potent Anticancer Activity
- (2010) Cheng-Jung Lai et al. CANCER RESEARCH
- Effect of additional inhibition of human epidermal growth factor receptor 2 with the bispecific tyrosine kinase inhibitor AEE788 on the resistance to specific EGFR inhibition in glioma cells
- (2010) Berezowska INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
- AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo
- (2010) Mylin A. Torres et al. INVESTIGATIONAL NEW DRUGS
- Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
- (2010) Timothy A. Yap et al. JOURNAL OF CLINICAL ONCOLOGY
- Discovery of 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide (CUDC-101) as a Potent Multi-Acting HDAC, EGFR, and HER2 Inhibitor for the Treatment of Cancer
- (2010) Xiong Cai et al. JOURNAL OF MEDICINAL CHEMISTRY
- A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer
- (2009) Olivier Rixe et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Discovery and Preclinical Evaluation of [4-[[1-(3-fluorophenyl)methyl]-1H-indazol-5-ylamino]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]carbamic Acid, (3S)-3-Morpholinylmethyl Ester (BMS-599626), a Selective and Orally Efficacious Inhibitor of Human Epidermal Growth Factor Receptor 1 and 2 Kinases
- (2009) Ashvinikumar V. Gavai et al. JOURNAL OF MEDICINAL CHEMISTRY
- Selectively Nonselective Kinase Inhibition: Striking the Right Balance
- (2009) Richard Morphy JOURNAL OF MEDICINAL CHEMISTRY
- BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models
- (2008) D Li et al. ONCOGENE
- Mechanism of Activation and Inhibition of the HER4/ErbB4 Kinase
- (2008) Chen Qiu et al. STRUCTURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now